Additionally, metabolites released from cancer cells modulate the immune environment, influencing T-cell function and responsiveness to immune checkpoint blockade therapies, such as programmed death-1(PD-1) and programmed cell death ligand 1(PD-L1) inhibitors (Figure 1). The gene discussed is CD274; the disease is cancer.